NF2 and mesothelioma: In this study, we demonstrate that mesothelioma cells with inactivating NF2 mutations are more susceptible to quinacrine in vitro, but the clinical efficacy for mesothelioma tumors with inactivating NF2 mutations will need to be assessed.